Objective: To evaluate, in patients with chronic migraine (CM) in real-world conditions, the persistence, effectiveness, and tolerability of erenumab, fremanezumab, and galcanezumab anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) and the persistence and effects of switching.
Background: Anti-CGRP mAbs represent a novel therapeutic approach to the management of CM; however, real-world data on persistence, effectiveness, and tolerability, especially after switching, are scarce.
Methods: This was a retrospective observational cohort study including all patients with CM treated with erenumab, fremanezumab, and/or galcanezumab in a tertiary hospital between January 2019 and December 2022.
J Eval Clin Pract
September 2024
Introduction: Integrated care pathways (ICPs) are crucial for delivering individualised care. However, the development of ICPs is challenging and must be well designed to provide the expected benefits. Regarding this, healthcare organisations are increasingly adopting management systems based on Lean Thinking to improve their organisational processes by eliminating non-value-added steps.
View Article and Find Full Text PDFHome hospitalization represents an alternative to traditional hospitalization, providing comparable clinical safety for hematological patients. At-home therapies can range from the delivery of intravenous antibiotics to more complex scenarios, such as the care during the early period after hematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy. Early discharge from conventional hospitalization is feasible and helps reduce hospital resources and waiting lists.
View Article and Find Full Text PDFThe use of allogeneic stem cell transplantation (allo-SCT) for the treatment of hematologic diseases is steadily increasing; however, allo-SCT has the downside of causing considerable treatment-related morbidity and mortality. Mobile technology applied to healthcare (mHealth) has proven to be a cost-effective strategy to improve care and offer new services to people with multimorbidity, but there are little data on its usefulness in allo-SCT recipients. Here we describe a new integrated healthcare model facilitated by an mHealth platform, EMMASalud-MY-Medula, and to report the results of a feasibility and usability pilot study.
View Article and Find Full Text PDFObjective: People living with human immunodeficiency virus could particularly benefit from mobile health (mHealth). The objective of the study was to contribute to the design and development of a new standard of care for people living with human immunodeficiency virus and the mHealth app needed to support it by 1) exploring the view of people living with human immunodeficiency virus and healthcare professionals on the possibilities of mHealth tools on HIV care, and 2) implementing their feedback into the new app and into the new journey of people living with human immunodeficiency virus.
Method: The study was conducted in two different phases: phase one was to apprise patients' and healthcare professionals' perspectives on mHealth using the qualitative methodology of the focus groups, whereas phase two aimed to implement their feedback into the application.